Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from August 16, 2025

Partial Published before the outcome was known, scored automatically when the window closed on November 14, 2025.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted
$103.17 Published $121.74 Target $102.69 Window close $109.50 Peak
$101.00 – $103.50Entry zone — fair-value band
$103.17Published — price the day we called it
$121.74Target — the price the thesis aimed for
$109.50Peak — highest point inside the window, not a realized return
$102.69Window close — end-of-window price, context only

What happened

Partial

Reached 34% of the predicted growth at its peak, without hitting the target.

Peak price
$109.50
peak on September 9, 2025 — not a realized return
Peak gain
+6.1%
peak, from the publication price
Window close
$102.69
end-of-window price, context only
Days to target
—
Window
August 16, 2025 – November 14, 2025

The thesis — published August 16, 2025

Predicted growth
+18%
over the measurement window
Target price
$121.74
the price the thesis aimed for
Entry zone
$101.00 – $103.50
the fair-value band we waited for
Price at publication
$103.17
published August 16, 2025
Confidence
62%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

The stock has fallen a lot even though the business has been growing for years and analysts remain positive. A major firm kept its Buy view with a $130 goal. The drop is tied to the FDA looking into a safety question about a defibrillator wire. Over the next three months, the bet is that steady growth wins out and the issue stays limited. If buying, keep losses small and wait for signs the price is starting to trend up again.

Primary drivers

  • A major bank reaffirmed its Buy rating and kept a $130 price target
  • Regulators are reviewing a possible safety issue with a defibrillator wire
  • The stock looks beaten down and could rebound over the next few weeks
  • The core business has been growing steadily for several years

How it played out

BSX: target was not reached

Lyra published BSX at $103.17 for a short-term window from 2025-08-16 to 2025-11-14. The thesis expected 18% growth. It pointed to a reaffirmed Buy view with a $130 goal, a beaten-down stock, steady business growth, and a regulatory review of a possible defibrillator wire safety issue that was expected to stay limited.

Inside the window, BSX rose to a peak of $109.50 on 2025-09-09, a 6.1% gain. That stayed below the $121.74 target. It never got there. The stock ended at $102.69 on 2025-11-14. The thesis partially played out because there was an early rebound, but the full target missed.

What happened during the window

On 2025-10-22, Investor's Business Daily reported Boston Scientific's third-quarter results, including adjusted earnings of $0.75 per share and revenue of $5.07 billion. On 2025-11-14, MarketWatch reported that BSX closed at $102.69 after falling 2.18% that day.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals